cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pliant Therapeutics Inc
4 own
5 watching
Current Price
$31.74
$-0.54
(-1.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,547.32M
52-Week High
52-Week High
36.64
52-Week Low
52-Week Low
3.965
Average Volume
Average Volume
0.46M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,547.32M
icon52-Week High36.64
icon52-Week Low3.965
iconAverage Volume0.46M
iconDividend Yield--
iconP/E Ratio--
What does the Pliant Therapeutics Inc do?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
How much money does Pliant Therapeutics Inc make?
News & Events about Pliant Therapeutics Inc.
Globe Newswire
2days ago
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced senior managements participation in the following ...
Globe Newswire
7days ago
Phase 1 clinical study initiation expected in the second quarter of 2023SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of ...
MarketBeat - AP News
15days ago
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment...
Globe Newswire
15days ago
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc.(Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering anddeveloping novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering...
Globe Newswire
15days ago
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human Resources Officer...
Frequently Asked Questions
Frequently Asked Questions
What is Pliant Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Pliant Therapeutics Inc shares?
plus_minus_icon
How can I buy Pliant Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Pliant Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Pliant Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Pliant Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Pliant Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Pliant Therapeutics Inc?
plus_minus_icon
What percentage is Pliant Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Pliant Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.74
$-0.54
(-1.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$21.01
$-0.22 (-1.04 %)
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$15.09
$-0.57 (-3.64 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$8.42
$-0.31 (-3.55 %)
KYMERA THERAPEUTICS INC
KYMERA THERAPEUTICS INC
$34.29
$-3.14 (-8.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$21.01
$-0.22 (-1.04 %)
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$15.09
$-0.57 (-3.64 %)
POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC
$8.42
$-0.31 (-3.55 %)
KYMERA THERAPEUTICS INC
KYMERA THERAPEUTICS INC
$34.29
$-3.14 (-8.39 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00